Terazosin Hydrochloride
Product Images NDC 53808-0306

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 53808-0306). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Terazosin HCl 2 mg Caps (Terazoin 2mg(apotex))

FDA Label Image

Terazosin HCl 5 mg Caps (Terazosin 5mg(apotex))

Terazosin HCL is a prescription medication available in the form of SMG CAP. It comes in a package of 30 capsules. The medication is manufactured by Apotex, and the lot number for this particular package is JF3880. The DO LOT number is 111320004. The packaging was done by DOH Central Pharmacy located in Tallahassee, FL 32204. The LT code is included in the packaging along with the lot number for tracking purposes.*

FDA Label Image

Terazosin HCl 1 mg Caps (Terazosin1mg (apotex))

Terazosin is a prescription drug sold in 30 tablets per bottle, with a concentration of milligrams that is not specified. The bottle has a lot number 020200K and an expiration date of 022810. The package was assembled by DOH Central Pharmacy and contains prescription medication for use only under the orders of a qualified healthcare provider.*

FDA Label Image

Chemical Structure (Terazosin Hydrochloride Capsules 1)

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

The text describes a figure and table of Study 1. The figure shows the mean change in total symptom score and mean increase in peak flow rate for Terazosin over a period of months. The table shows the baseline values for both parameters. It also mentions that Terazosin was more effective than the placebo group, with a p-value of less than 0.05.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

This is a figure presenting the mean change in total symptoms score from baseline in a long-term, open-label, non-placebo controlled study that involved 494 participants. The graph shows the mean change from baseline over a period of 30 months, with measurements taken at each month interval. The mean baseline was 10.7, and there was a statistically significant improvement in symptoms, with p <0.05.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

This is a graph showing the mean change in peak flow rate from the baseline in a long-term, open-label, non-placebo controlled study. The X-axis shows the months (from 0 to 30) and the Y-axis shows the mean change from baseline. The mean baseline value is 99. There is a statistical significance (p<0.05) at some months compared to the baseline.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.